Whalesbook
Poultry Segment Drives Strong Q4 Performance
Hester Biosciences reported significant Q4 FY26 results, with its Poultry segment revenue climbing 41% year-on-year. This strong performance was fueled by successful market penetration efforts and the licensing of new H9N2 Avian Influenza vaccines. For the full fiscal year FY26, the Poultry segment saw 21% growth.
Animal Health Division Eyes Turnaround
The Animal Healthcare division’s revenue was impacted by delays in government tenders earlier in FY26. Despite these challenges, the company fulfilled significant supply orders, providing 6.3 crore PPR doses in Q4 FY26. Management anticipates a turnaround for this division starting in Q1 FY27.
Debt Reduction and Receivables Management
Financially, Hester Biosciences successfully reduced its net debt to ₹70 crore by the end of Q4 FY26. This brings the company’s debt-to-equity ratio to a healthy 0.19, signaling improved financial health. Operationally, the company wrote off INR 6.5 crore in old, non-recovered debts. Receivables stood at INR 92 crore, which management attributes to high Q4 sales. Efforts are underway to reduce debtor days and improve working capital management.
Strategic Moves and Infrastructure
Earlier in May 2023, Hester Biosciences strategically divested its stake in Texas Lifesciences LLC. This move signals a focus on its core biologicals business. The company has also invested in its infrastructure, including its Fill-Finish and BSL-3 facilities, to boost drug product manufacturing capacity and support its biologics portfolio.
Future Outlook and Revenue Goals
Investors can anticipate a potential recovery in the Animal Health segment's revenue from the first quarter of FY27. The company's overall financial leverage has decreased significantly with the reduced net debt. Management views the poultry segment as a sustainable revenue base. Hester Biosciences is also expanding its presence in Africa, participating in the VITAL 2 program. A key objective remains achieving a more balanced revenue mix, aiming for a 50-50 split between Poultry and Animal Healthcare.
Potential Challenges Ahead
The Animal Health segment's revenue remains susceptible to fluctuations, largely due to its reliance on government tenders. Additionally, rising raw material costs, potentially influenced by global geopolitical factors and supply chain disruptions, could impact profit margins. The substantial receivables of INR 92 crore require close monitoring to ensure efficient working capital management. Evolving global regulatory standards may also necessitate unplanned future capital expenditures.
Industry Landscape
Key players in the animal health sector include global giant Zoetis Inc., known for its consistent growth, and domestic competitor Indian Immunologicals Ltd., which is expanding vaccine production, highlighting the competitive animal biologics market.
Key Financials at a Glance
- Poultry segment revenue grew 41% in Q4 FY26 and 21% for the full fiscal year FY26.
- Net debt was ₹70 crore as of Q4 FY26, with a debt-to-equity ratio of 0.19.
- Receivables stood at ₹92 crore as of Q4 FY26.
- A bad debt write-off of ₹6.5 crore was recorded in Q4 FY26.
Investor Watchlist
Investors will be monitoring Q1 FY27 results for signs of recovery in the Animal Health division. Progress in reducing debtor days and improving receivables management will be crucial. Sustaining poultry margins amidst cost pressures and assessing the impact of global supply chain disruptions on raw material costs are also key. Developments in the Petcare segment and any future capital investment needs driven by regulatory changes will also be watched.